Cytomegalovirus (CMV) infection and risk of mortality in allogeneic hematopoietic stem cell transplantation (Allo-HSCT): A systematic review, meta-analysis, and meta-regression analysis
- PMID: 31247126
- DOI: 10.1111/ajt.15515
Cytomegalovirus (CMV) infection and risk of mortality in allogeneic hematopoietic stem cell transplantation (Allo-HSCT): A systematic review, meta-analysis, and meta-regression analysis
Abstract
Controversy surrounds the potential association between cytomegalovirus (CMV) infection and increased risk of mortality after allogeneic hematopoietic stem cell transplantation (Allo-HSCT). A systematic literature search was conducted using the PubMed, EMBASE, and Web of Science databases, assessing the association between CMV infection, as documented by the pp65 antigenemia assay or by polymerase chain reaction (PCR) using blood specimens, and overall mortality (OM) and nonrelapse mortality (NRM) in the allo-HSCT setting. Pooled effects were estimated using the generic inverse variance random effects model. Heterogeneity was evaluated by Cochrane's Q test and I2 statistics. The source of heterogeneity was investigated by meta-regression and subgroup analyses. Twenty-six of 1367 studies fulfilled eligibility criteria. CMV infection identified by PCR monitoring was significantly associated with an increased risk of OM and NRM (hazard ratio 1.47, 95% confidence interval [1.20-1.81], P ≤ .001; hazard ratio 1.68, 95% confidence interval [1.14-2.49], P = .05, respectively). In this setting, the use of preemptive antiviral therapy (PET) resulted in a twofold increased risk of OM and NRM. The estimated effect sizes were associated with allo-HSCT modalities. Although our analyses point to an association between CMV infection and an increased risk of OM and NRM in allo-HSCT recipients, the high heterogeneity across studies prevented drawing of robust conclusions on this matter.
Keywords: bone marrow/hematopoietic stem cell transplantation; clinical research/practice; infection and infectious agents - viral: cytomegalovirus (CMV); infectious disease; meta-analysis.
© 2019 The American Society of Transplantation and the American Society of Transplant Surgeons.
Similar articles
-
Cytomegalovirus DNAemia and risk of mortality in allogeneic hematopoietic stem cell transplantation: Analysis from the Spanish Hematopoietic Transplantation and Cell Therapy Group.Am J Transplant. 2021 Jan;21(1):258-271. doi: 10.1111/ajt.16147. Epub 2020 Jul 15. Am J Transplant. 2021. PMID: 32812351
-
Patients with refractory cytomegalovirus (CMV) infection following allogeneic haematopoietic stem cell transplantation are at high risk for CMV disease and non-relapse mortality.Clin Microbiol Infect. 2015 Dec;21(12):1121.e9-15. doi: 10.1016/j.cmi.2015.06.009. Epub 2015 Jun 17. Clin Microbiol Infect. 2015. PMID: 26093077
-
Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.Biol Blood Marrow Transplant. 2015 Nov;21(11):2008-16. doi: 10.1016/j.bbmt.2015.07.019. Epub 2015 Jul 26. Biol Blood Marrow Transplant. 2015. PMID: 26211985
-
The association of cytomegalovirus infection and cytomegalovirus serostatus with invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients: a systematic review and meta-analysis.Clin Microbiol Infect. 2022 Mar;28(3):332-344. doi: 10.1016/j.cmi.2021.10.008. Epub 2021 Nov 6. Clin Microbiol Infect. 2022. PMID: 34752926 Review.
-
Optimizing the treatment of cytomegalovirus infection in allo-HSCT recipients.Expert Rev Clin Immunol. 2023 Feb;19(2):227-235. doi: 10.1080/1744666X.2023.2161510. Epub 2023 Jan 1. Expert Rev Clin Immunol. 2023. PMID: 36541485 Review.
Cited by
-
Herpesvirus Screening in Childhood Hematopoietic Transplant Reveals High Systemic Inflammation in Episodes of Multiple Viral Detection and an EBV Association with Elevated IL-1β, IL-8 and Graft-Versus-Host Disease.Microorganisms. 2022 Aug 22;10(8):1685. doi: 10.3390/microorganisms10081685. Microorganisms. 2022. PMID: 36014102 Free PMC article.
-
Alternative donor peripheral blood stem cell transplantation for the treatment of high-risk refractory and/or relapsed childhood acute leukemia: a randomized trial.Exp Hematol Oncol. 2020 Apr 6;9:5. doi: 10.1186/s40164-020-00162-6. eCollection 2020. Exp Hematol Oncol. 2020. PMID: 32280563 Free PMC article.
-
Epstein-Barr virus and cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma: the prevalence and impacts on outcomes : EBV and CMV reactivation post allo-HCT in NHL.Ann Hematol. 2021 Nov;100(11):2773-2785. doi: 10.1007/s00277-021-04642-5. Epub 2021 Sep 4. Ann Hematol. 2021. PMID: 34480615 Free PMC article.
-
Clinical features and prognosis of systemic lupus erythematosus complicated by active cytomegalovirus infection: a retrospective cohort study.Front Immunol. 2024 Feb 28;15:1323923. doi: 10.3389/fimmu.2024.1323923. eCollection 2024. Front Immunol. 2024. PMID: 38481991 Free PMC article.
-
Features of cytomegalovirus infection and evaluation of cytomegalovirus-specific T cells therapy in children's patients following allogeneic hematopoietic stem cell transplantation: A retrospective single-center study.Front Cell Infect Microbiol. 2022 Oct 20;12:1027341. doi: 10.3389/fcimb.2022.1027341. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 36339340 Free PMC article.
References
REFERENCES
-
- Pérez-Romero P, Blanco P, Giménez E, Solano C, Navarro D. An update on the management and prevention of cytomegalovirus infection following allogeneic hematopoietic stem cell transplantation. Future Virol. 2015;10(2):113-134.
-
- Chemaly RF, Ullmann AJ, Stoelben S, et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med. 2014;370(19):1781-1789.
-
- Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377(25):2433-2444.
-
- Green ML, Leisenring WM, Xie H, et al. CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood. 2013; https://doi.org/10.1182/blood-2013-2002-487074.
-
- Sousa H, Boutolleau D, Ribeiro J, et al. Cytomegalovirus infection in patients who underwent allogeneic hematopoietic stem cell transplantation in Portugal: a five-year retrospective review. Biol Blood Marrow Transplant. 2014;20(12):1958-1967.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical